Atezolizumab + cobimetinib in locally advanced or metastatic CRC (Phase III IMblaze370) - primary endpoint analysis

Patients:

• 360 patients with 
• locally advanced or metastatic CRC >= 2 prior treatments

Treatment arms - randomized (2:1:1) to

• atezolizumab + cobimetinib vs. atezolizumab vs. regorafenib (control)

Primary endpoint: OS

Results:

• >95% patients were MSS
• Combo failed to meet the primary endpoint of OS compared to regorafenib (https://www.roche.com/media/store/releases/med-cor-2018-05-10.htm).
• Safety results were consistent with the known profiles of the individual drugs
• Roche has halted patient recruitment to cohort 4 (atezolizumab + cobimetinib) in the phase 2 MODUL trial since Apr. 2018 (https://www.biospace.com/article/roche-halts-colorectal-cancer-trial-recruitment-after-4-patient-deaths/)